DoD tests AI models that make it easy to switch from vendors like Palantir
Alterity Therapeutics Limited (NASDAQ:ATH) announced today that its CEO will deliver a corporate update focusing on ATH434, the company's lead drug candidate.
The update will provide stakeholders with information on the current development status of ATH434, which is being developed by the Melbourne-based biopharmaceutical company. Alterity, formerly known as Prana Biotechnology Ltd, is classified as a development stage enterprise specializing in pharmaceutical preparations.
The announcement was made in a Form 6-K filing with the U.S. Securities and Exchange Commission on Monday. The filing did not provide specific details about the timing or format of the CEO's update, nor did it disclose what particular aspects of the ATH434 program would be addressed.
Alterity Therapeutics is headquartered in Melbourne, Australia, with its principal executive office located at Level 14, 350 Collins Street. The company files annual reports under Form 20-F with the SEC.
The Form 6-K was signed by Geoffrey P. Kempler, Chairman of Alterity Therapeutics Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.